November 8, 2011 — Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Read more.

November 2, 2011 — Micell Technologies Announces Presentation of Clinical Data at TCT 2011
Read more.

July 26, 2011 — Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent^® Drug-Eluting Coronary Stent
Read more.

June 29, 2011 — Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent^® Drug-Eluting Coronary Stent Based on Early Clinical Data
Read more.

May 11, 2011 — Micell Technologies Reports Preclinical Data for MiStent^TM Drug-Eluting Coronary Stent to be Presented at EuroPCR
Read more.

February 17, 2011 — Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent^TM Drug-Eluting Coronary Stent (DES)
Read more.

November 29, 2010 — Micell Technologies Enrolls First Patient in DESSOLVE I First-In-Human Study of MiStent DES.
Read more.

September 21, 2009 — Micell Receives $15 Million Equity Investment.
Read more.

March 4, 2009 — The Micell Rapid Absorption Polymer DES System to be Presented at CRT 2009.
Read more.

January 12, 2009 — Micell Forges Strategic Agreement to Develop Advanced Drug-eluting Atents and Balloons.
Read more.